Mazdutide
Also known as: IBI362, LY3305677, LY3305677, Xinermei
Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; incretin-based peptide therapeutic
What it is
Mazdutide is an investigational weight-loss and diabetes drug being studied in clinical trials, particularly in Asian populations. It activates two hormone pathways at once to cut appetite and burn more calories. Not FDA-approved; Phase 2/3 clinical trials completed or ongoing; in active clinical development.
The scientific side
Mazdutide is a once-weekly dual agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). GLP-1R activation stimulates insulin secretion, lowers blood glucose, and reduces appetite. GCGR activation is hypothesized to enhance energy expenditure and stimulate lipolysis and mitochondrial fat oxidation, potentially augmenting weight loss beyond that achieved with GLP-1R monoagonism alone (PMID 41028652, PMID 41478576, PMID 41025406). Preclinical multi-omics analysis in diabetic mice suggests dual GLP-1/GCGR activation engages molecular pathways involved in neuroprotection, energy metabolism, and synaptic plasticity. In animal models of metabolic dysfunction-associated steatotic liver disease (MASLD), mazdutide alleviated endoplasmic reticulum stress via the PERK pathway, suppressed NF-κB-mediated inflammation, and downregulated key lipogenic regulators including SREBP-1, C/EBPβ, and PPARγ. Tubular GCGR signaling has been shown to confer renoprotection in diabetic kidney disease by maintaining V-ATPase (V1-V0) assembly and lysosomal acidification.
Class: Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; incretin-based peptide therapeutic
Administration & storage
- Administration
- Subcutaneous injection once weekly (PMID: 40421736)Subcutaneous injection once weekly (PMID: 41407859)Subcutaneous injection once weekly (PMID: 41407860)Subcutaneous injection once weekly (PMID: 42251595)Subcutaneous injection once weekly (PMID: 41875890)Subcutaneous injection once weekly (PMID: 40832785)Subcutaneous injection once weekly (PMID: 42628555)Subcutaneous injection once weekly (PMID: 35750681)Subcutaneous injection once weekly (PMID: 36247927)Subcutaneous injection (every 3 days in animal modelPMID: 40828048)
- Storage
- Storage conditions for mazdutide are not described in the reviewed abstracts.
- Cautions
- Gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) are the most commonly reported treatment-emergent adverse events across clinical trials, and are generally mild to moderate in severity (PMID: 40421736, PMID: 41407859, PMID: 41407860, PMID: 42251595).,Treatment discontinuation due to adverse events occurred in up to 20% of participants receiving the 16 mg dose in one phase 2 trial, primarily due to gastrointestinal disorders.,Cardiovascular considerations: GCGR/GLP-1R dual agonists, including mazdutide, may increase heart rate to a similar extent as GLP-1R monoagonists; cardiovascular outcomes trial data are not yet available for mazdutide.,Evidence for mazdutide in adolescents is limited to a single case report; no randomized controlled trial data in pediatric populations were identified.,Data on long-term (beyond 60 weeks) cardiovascular safety, mortality, and multi-ethnic generalizability are currently lacking; most trials were conducted in Chinese adults.,Sterile technique is required for subcutaneous injection to minimize infection risk.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Weight management in adults with overweight or obesity (without type 2 diabetes) Human RCT
- 610 adults (BMI ≥28 or BMI 24–<28 with ≥1 comorbidity); 4 mg or 6 mg once-weekly subcutaneous mazdutide vs. placebo for 48 weeks. At week 32, mean body weight change: -10.09% (4 mg) and -12.55% (6 mg) vs. +0.45% (placebo). At week 48: -11.00% (4 mg) and -14.01% (6 mg) vs. +0.30% (placebo). 73.9% and 82.0% of participan PMID 40421736 Ji et al., NEJM (2025) — GLORY-1 phase 3 trial
- 461 participants (BMI ≥30, 16.1% with T2D); 9 mg once-weekly subcutaneous mazdutide vs. placebo for 60 weeks. Mean body weight change at week 60: -16.65% (mazdutide) vs. -1.50% (placebo); difference -15.15% (P<0.001). 84.3% of mazdutide participants achieved ≥5% weight reduction vs. 33.1% placebo. PMID 42251595 Gao et al., JAMA (2026) — GLORY-2 phase 3 trial
- 248 participants; 24-week treatment with mazdutide 3 mg, 4.5 mg, or 6 mg vs. placebo. Percentage change in body weight: -6.7% (3 mg), -10.4% (4.5 mg), -11.3% (6 mg) vs. +1.0% (placebo); treatment difference vs. placebo -7.7% to -12.3% (all p<0.0001). PMID 38092790 Ji et al., Nature Communications (2023) — phase 2 trial
- 80 participants (BMI ≥30, no diabetes); mazdutide 9 mg vs. placebo for 24 weeks. Mean weight change: -12.78% (mazdutide) vs. +1.80% (placebo); treatment difference -14.58% (95% CI -18.00, -11.16; p<0.0001). 81.7% of mazdutide participants achieved ≥5% weight reduction vs. 0% placebo. PMID 41875890 Ji et al., Med (2026) — phase 2 trial (9 mg)
- 32 adults with overweight/obesity without diabetes; once-weekly subcutaneous mazdutide up to 16 mg vs. placebo for 20 weeks. Mean body weight change: -20.0% (Cohort 1) and -21.0% (Cohort 2) vs. -0.1% (placebo; p<0.001). 66.7% and 75.0% of mazdutide participants achieved ≥15% weight loss. PMID 40832785 Bhattachar et al., Diabetes Obesity & Metabolism (2025) — phase 1 trial (up to 16 mg)
- 179 US adults with obesity/overweight without T2D; once-weekly subcutaneous mazdutide 3–6 mg, 10 mg, or 16 mg vs. placebo for 48 weeks. At 32 weeks, LS mean body weight change: -7.3% (3–6 mg), -15.6% (10 mg), -18.1% (16 mg) vs. -0.9% (placebo); all comparisons p<0.0001. PMID 42628555 Hsia et al., Lancet Diabetes & Endocrinology (2026) — US-based phase 2 trial
- 24 participants; 9 mg cohort: mean weight change -11.7% vs. -1.8% (placebo) at week 12 (ETD -9.8%; p=0.0002). 10 mg cohort: mean weight change -9.5% vs. -3.3% (placebo) at week 16 (ETD -6.2%; p=0.024). PMID 36247927 Ji et al., EClinicalMedicine (2022) — phase 1b trial (9 mg and 10 mg)
- Glycaemic control in adults with type 2 diabetes (T2D) Human RCT
- 320 participants with T2D (mean HbA1c 8.24%); 4 mg or 6 mg mazdutide vs. placebo once-weekly subcutaneous for 24 weeks. HbA1c change: -1.57% (4 mg) and -2.15% (6 mg) vs. -0.14% (placebo); treatment differences -1.43% and -2.02% (both P<0.0001). Weight loss: -5.61% (4 mg) and -7.81% (6 mg) vs. -1.26% (placebo). PMID 41407859 Zhu et al., Nature (2026) — phase 3 trial vs. placebo
- 731 participants with T2D; 4 mg or 6 mg mazdutide vs. 1.5 mg dulaglutide for 28 weeks. HbA1c difference vs. dulaglutide: -0.24% (4 mg; P=0.0032) and -0.30% (6 mg; P=0.0003). Body weight difference vs. dulaglutide: -3.78% (4 mg) and -5.76% (6 mg) (both P<0.0001). PMID 41407860 Guo et al., Nature (2026) — phase 3 trial vs. dulaglutide
- 250 Chinese adults with T2D; 3 mg, 4.5 mg, or 6 mg mazdutide vs. placebo or dulaglutide 1.5 mg for 20 weeks. Mean HbA1c change: -1.41% to -1.67% with mazdutide vs. +0.03% with placebo (all P<0.0001). Body weight change: up to -7.1% with mazdutide vs. -1.4% with placebo. PMID 37943529 Zhang et al., Diabetes Care (2024) — phase 2 trial
- 43 Chinese patients with T2D; once-weekly subcutaneous IBI362 3.0, 4.5, or 6.0 mg vs. placebo or dulaglutide 1.5 mg for 12 weeks. HbA1c, fasting plasma glucose, and post-MTT glucose were reduced from baseline in all three IBI362 cohorts. PMID 35750681 Jiang et al., Nature Communications (2022) — phase 1b trial (IBI362/LY3305677)
- Treatment of type 2 diabetes and obesity (combination endpoint: HbA1c <7.0% and ≥10% weight reduction) Human RCT
- Randomized phase 3 trial; 349 participants with T2D and obesity (BMI ≥28 kg/m²); mazdutide 6 mg vs. semaglutide 1 mg once weekly for 32 weeks (plus 24-week extension). Primary endpoint: proportion achieving HbA1c <7.0% and ≥10% weight reduction at week 32. Results pending. PMID 41260459 Luo et al., Contemporary Clinical Trials (2026) — DREAMS-3 trial protocol
- Metabolic dysfunction-associated steatotic liver disease (MASLD) / fatty liver Animal studies only
- In a high-fat diet MASLD mouse model, subcutaneous mazdutide (100, 200, or 400 µg/kg for 4 weeks) significantly ameliorated systemic and hepatic lipid metabolism, reduced liver injury markers and hepatic steatosis, and mitigated inflammation and oxidative stress. Mechanistically, mazdutide alleviated ER stress via the PMID 41901218 Gan et al., Pharmaceuticals (2026)
- In high-fat diet C57BL/6 male mice, subcutaneous mazdutide administered every 3 days for 4 weeks produced a greater reduction in MRI-derived liver proton density fat fraction (PDFF) vs. semaglutide (median change -5.59% vs. -3.30%; P=0.02). Decreases in R2* (liver iron) did not significantly differ between groups. PMID 40828048 Xia et al., Radiology (2025) — multiparametric MRI in high-fat diet mice
- Diabetes-associated cognitive dysfunction Animal studies only
- In male db/db mice (T2DM model), mazdutide significantly improved cognitive performance vs. dulaglutide in behavioral tests. Pathological assessments showed improved neuronal structure and brain tissue integrity. Multi-omics identified molecular pathways involved in neuroprotection, energy metabolism, and synaptic plas PMID 40479843 Dong et al., EBioMedicine (2025)
- Diabetic kidney disease (DKD) / renoprotection Animal studies only
- Using tubule-specific GCGR loss- and gain-of-function mouse models and human kidney samples, this study showed that tubular GCGR signaling exerts a renoprotective role in DKD via a GCGR-ATP6V1A-lysosome axis. Clinical trials of dual GLP-1R/GCGR agonists including mazdutide were noted to show kidney benefits in patients PMID 42555719 Qu et al., Science Advances (2026)
- Hyperuricemia reduction Mixed
- In a 15-year-old male with obesity, T2DM, and hyperuricemia, dose-escalated mazdutide (2 mg → 4 mg → 6 mg subcutaneously once weekly) plus metformin and insulin over 36 weeks reduced serum uric acid by 37.00%, weight by 16.8 kg, and HbA1c by 21.88%. PMID 41030857 Cheng et al., Frontiers in Endocrinology (2025) — case report
- Systematic review of 9 RCTs found mazdutide improved uric acid levels (among other metabolic outcomes) vs. placebo or active comparators in adults with overweight/obesity and/or T2D. PMID 42410325 Kamrul-Hasan et al., Diabetes Obesity & Metabolism (2026) — meta-analysis
- Obstructive sleep apnoea and alcohol use disorder (investigational) Human observational
- Mazdutide is noted to be under clinical evaluation for use in the treatment of metabolic dysfunction-associated fatty liver disease, obstructive sleep apnoea, and alcohol use disorder, in addition to its approved indications in China. PMID 41028652 Shirley, Drugs (2025) — first approval review
Safety signals
- Nausea: most common gastrointestinal adverse event; reported in 46.9% (9 mg, 60-week trial), 50.0% (9 mg, 24-week phase 2), and 23% (6 mg, 20-week phase 2 T2D) of mazdutide-treated participants PMID 42251595
- Vomiting: reported in 53.1% (9 mg, 60-week GLORY-2 trial) and 36.7% (9 mg, 24-week phase 2) of mazdutide-treated participants; predominantly mild to moderate in severity PMID 42251595
- Diarrhea: reported in 39.4% (9 mg, 60-week GLORY-2 trial), 38.3% (9 mg, 24-week phase 2), and 36% (6 mg, 20-week T2D phase 2) of mazdutide-treated participants PMID 42251595
- Decreased appetite: reported in 29% of mazdutide-treated participants in the 20-week T2D phase 2 trial; also commonly reported in other trials PMID 37943529
- Hypoglycemia: reported in 10% of mazdutide-treated participants vs. 8% with placebo in the 20-week T2D phase 2 trial PMID 37943529
- Treatment discontinuation due to adverse events: 2.9% of participants in the 9 mg GLORY-2 60-week trial (vs. 0% placebo); up to 20% with 16 mg dose in US phase 2 trial, primarily due to gastrointestinal disorders PMID 42251595
- Upper respiratory tract infection: commonly reported TEAE in phase 1b and phase 2 trials PMID 36247927
- Increased treatment-emergent adverse events (TEAEs) overall vs. placebo: pooled OR 2.52 (95% CI 1.92–3.30) for mazdutide and cotadutide combined vs. placebo in meta-analysis; no significant increase in serious adverse events (OR 1.03) PMID 38740695
- Vomiting (pooled, meta-analysis): significantly higher odds vs. placebo (OR 6.05; 95% CI 3.52–10.40) for GLP-1/GCGR dual agonists (mazdutide and cotadutide combined) PMID 38740695
- Heart rate increase: clinical studies of mazdutide have generally found increased heart rate to a similar extent as GLP-1R monoagonists; one other dual agonist (not mazdutide) was discontinued partly due to unacceptably large increases in heart rate and QTc prolongation PMID 42535526
- Abdominal distension and urinary tract infection: reported as TEAEs in phase 1b trial of mazdutide up to 10 mg PMID 36247927
- No serious adverse events were reported in the phase 1 trial of mazdutide up to 16 mg (n=24) or in the adolescent case report PMID 40832785
Contraindications
- No specific contraindications are explicitly stated in the reviewed abstracts. Phase 2 and phase 3 trials generally enrolled adults aged 18–75 years and excluded those with type 1 diabetes; specific contraindications were not enumerated in available abstracts. PMID 40421736
Protocol
No community protocol on record. In clinical studies, Mazdutide was dosed at 4 mg or 6 mg once weekly Subcutaneous injection (PMID 41407860).
All studies (23)
- PMID 35750681 Human RCT
Glycaemic control in adults with type 2 diabetes (T2D) - PMID 36247927 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 37943529 Human RCT
Glycaemic control in adults with type 2 diabetes (T2D) - PMID 38092790 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 40421736 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 40832785 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 41260459 Human RCT
Treatment of type 2 diabetes and obesity (combination endpoint: HbA1c <7.0% and ≥10% weight reductio - PMID 41407859 Human RCT
Glycaemic control in adults with type 2 diabetes (T2D) - PMID 41407860 Human RCT
Glycaemic control in adults with type 2 diabetes (T2D) - PMID 41875890 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 42251595 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 42628555 Human RCT
Weight management in adults with overweight or obesity (without type 2 diabetes) - PMID 41028652 Human observational
Obstructive sleep apnoea and alcohol use disorder (investigational) - PMID 41030857 Mixed
Hyperuricemia reduction - PMID 42410325 Mixed
Hyperuricemia reduction - PMID 38740695
Increased treatment-emergent adverse events (TEAEs) overall vs. placebo: pooled OR 2.52 (95% CI 1.92–3.30) for mazdutide and cotadutide combined vs. placebo in - PMID 40479843 Animal studies only
Diabetes-associated cognitive dysfunction - PMID 40828048 Animal studies only
Metabolic dysfunction-associated steatotic liver disease (MASLD) / fatty liver - PMID 41025406
- PMID 41478576
- PMID 41901218 Animal studies only
Metabolic dysfunction-associated steatotic liver disease (MASLD) / fatty liver - PMID 42535526
Heart rate increase: clinical studies of mazdutide have generally found increased heart rate to a similar extent as GLP-1R monoagonists; one other dual agonist - PMID 42555719 Animal studies only
Diabetic kidney disease (DKD) / renoprotection